The U.S. life sciences industry is entering one of its most exciting - yet challenging - periods in decades. With capital Markets favouring disciplined innovators and regulators focusing on real clinical improvements, these pressures will define the next generation of global healthcare leaders.

Using the real-world experience of Medcura, a Maryland-based biosurgery company developing new technology for spinal surgery, Jim Buck will share what it takes today to develop, fund, and move forward groundbreaking medical devices in the U.S.

Jim will explore the cooperation between American innovators and European scientific, regulatory, and investment communities. As medtech platforms expand globally earlier in their development, combining the U.S. venture capital rigor, Europe’s technical expertise and its increasing investment appetite is becoming a major competitive advantage.

Attendees will gain a candid view of how companies like Medcura navigate these Europe-Atlantic dynamics and why the next wave of value creation will belong to those who understand both worlds.